QCM
HAE icon

Qsemble Capital Management’s Haemonetics HAE Stock Holding History

Qsemble Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,997
Closed -$244K – 536
2025
Q3 		$244K Buy
+4,997
New +$309K 0.02% 418
2025
Q2 		– Sell
-3,553
Closed -$226K – 499
2025
Q1 		$226K Buy
+3,553
New +$242K 0.02% 401
2024
Q3 		– Sell
-5,331
Closed -$441K – 452
2024
Q2 		$441K Buy
+5,331
New +$469K 0.08% 309

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Qsemble Capital Management's HAE Position: Q4 2025 in Review

Qsemble Capital Management sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 4,997 shares — an estimated $244K sold.

Qsemble Capital Management first reported a position in HAE in Q2 2024 and held it in 3 quarters. The position peaked at $441K in Q2 2024. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

  • Qsemble Capital Management reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
  • Qsemble Capital Management sold 4,997 Haemonetics shares in Q4 2025, an estimated $244K.
  • Qsemble Capital Management first reported a position in Haemonetics in Q2 2024 and held it in 3 quarters.
  • Qsemble Capital Management's Haemonetics position peaked at $441K in Q2 2024.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Qsemble Capital Management's 13F filing for Q4 2025, filed 5 Feb 2026.